For research use only. Not for therapeutic Use.
6-Desacetyl-6-Bromo Palbociclib(CAT: C000623) is an impurity of Palbociclib,(also known as compound number PD-0332991) is an experimental drug for the treatment of breast cancer being developed by Pfizer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6. Also, it is derived from 6-Bromo-2-chloro-8-cyclopentyl-5-methylpyrido-[2,3-d]pyrimidin-7(8H)-one, which is used to prepare pyridino[2,3-d]pyrimidin-7(8H)-one derivative as CDK4 and/or CDK6 inhibitors useful in the treatment of diseases.
Catalog Number | C000623 |
CAS Number | 851067-56-6 |
Synonyms | 6-Bromo-8-cyclopentyl-5-methyl-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]pyrido[2,3-d]pyrimidin-7(8H)-one; Palbociclib Impurity F |
Molecular Formula | C₂₂H₂₆BrN₇O |
Purity | ≥95% |
Solubility | Aqueous Acid (Slightly), DMSO (Slightly, Heated), DMF (Slightly, Heated) |
Appearance | Off-White to Yellow Solid |
Storage | -20°C, Inert atmosphere |
Reference | Finn, R., et al.: Breast Cancer Res., 11, 5 (2009); Li, X., et al.: PCT Int. Appl., WO 2014183520 A1 20141120 (2014); |